MenopauseDigest — Connected Through ChangeEvidence Radar Active

Evidence Radar active · 81 validated items in archive

Validated
Evidence.
Real Understanding.

MenopauseDigest monitors, validates, and interprets the evidence shaping the menopause transition. Our Evidence Radar continuously scans clinical research, guidance, and reporting—so you can see what is established, what is emerging, and what remains uncertain.

MenopauseDigest is not a destination for answers. It is a place for understanding.

Why MenopauseDigest Exists

Between rigor and reach sits a widening Noise Gap.

For women navigating perimenopause and menopause, information arrives from every direction. Social media offers confidence and certainty, often without accountability. Medical research offers rigor and depth, but in language that assumes clinical training and time most people do not have.

MenopauseDigest was created in response to that failure. We exist to provide Intelligence for the Transition—not opinions, not prescriptions, and not products. We use technology and disciplined editorial standards to gather, interrogate, and translate menopause research so women can understand what is known, what is uncertain, and what questions are worth asking.

Read Our Story →

Trust Framework

Credibility before content.

Understanding requires trust, and trust requires standards. MenopauseDigest is deliberately separated from sponsored content, commercial influence, unverified claims, and algorithm-driven health feeds. These are the standards that make the rest of the platform meaningful.

Non-Commercial Feed

No sponsorships, no affiliate deals, no commercial influence shaping what we cover.

Pure Editorial

Independent editorial judgment. No paid placements, no advertorials, no hidden incentives.

Direct Sourcing

Every item links to its primary source so you can verify the evidence yourself.

Local Privacy

Search history, reflections, and translations stay on your device—never on our servers.

Evidence Classification Framework

Understanding the maturity of the evidence.

Classification is not about organizing content. It is about helping you judge how much weight any finding deserves. Every item is tagged by domain and by epistemic status so you can see, at a glance, how settled or how provisional the evidence really is.

Epistemic Status

Established / Validated

Findings supported by replication and consensus clinical guidance—evidence you can lean on with confidence.

Recent / Emerging

New studies and developing signals worth knowing about, but not yet settled. We flag them so you can weigh the uncertainty.

Domains

Medical

Clinical research, hormone therapy, symptoms, and treatment evidence.

Wellness

Lifestyle, nutrition, exercise, and behavioral interventions.

Relational

Partnership, family, and the relational dimensions of the transition.

Society

Workplace, policy, and cultural framing of midlife health.

Evidence Archive

Organized by evidence quality, not popularity.

The archive is not a feed and not a ranking. Each item is classified by the maturity of its evidence so you can see, at a glance, what deserves confidence and what deserves continued observation. The archive answers what is happening. The Editorial Series help answer what it means.

Established / Validated

Supported by replication, consensus guidance, or enduring research.

Recent / Emerging

Important and noteworthy, but still developing. Weigh with care.

Established / Validated

VerifiedMedical

Both High and Low Testosterone Tied to Higher Atrial Fibrillation Risk

A narrative review published in the Journal of the Endocrine Society suggests a U-shaped relationship between testosterone levels and the risk of atrial fibrillation in men. The findings indicate that both low testosterone and high testosterone levels, including those resulting from replacement therapy, are associated with increased heart rhythm risks.

jamanetwork.com

Last reviewed Sep 26, 2026

Established / Validated

VerifiedMedical

Oral vs Transdermal Hormone Therapy and Thrombotic Disease Risk: A Nationwide Study

A large-scale Danish study analyzed the risk of blood clots, stroke, and heart attack in women aged 50-69 using various forms of menopausal hormone therapy. The research compared oral and transdermal (patch) methods across nearly two decades of health registry data.

bmj.com

Peer-Reviewed Journal

Last reviewed Sep 25, 2026

Established / Validated

VerifiedMedical

British Menopause Society Guidelines for Unscheduled Bleeding on HRT

This joint guideline outlines clinical protocols for assessing and managing unscheduled bleeding in women using hormone replacement therapy. It establishes criteria for urgent investigations based on individual risk factors, bleeding duration, and endometrial thickness.

thebms.org.uk

Last reviewed Sep 24, 2026

Established / Validated

VerifiedMedical

British Menopause Society Responds to Updated NICE Guideline NG23

The British Menopause Society (BMS) has issued a response to the November 2024 update of the NICE Guideline on Menopause Identification and Management. While welcoming the update, the BMS highlights specific limitations in the revised guidance that healthcare providers should consider.

thebms.org.uk

Last reviewed Sep 21, 2026

Established / Validated

VerifiedMedical

Hormone Replacement Therapy: Clinical Indications and Safety Profiles

Hormone replacement therapy (HRT) is the primary FDA-approved treatment for moderate-to-severe menopausal vasomotor symptoms, such as hot flashes and night sweats. While HRT is effective for symptom relief and osteoporosis prevention, it is not indicated for the prevention of chronic diseases like cardiovascular disease or dementia.

ncbi.nlm.nih.gov

Government Health Org

Last reviewed Sep 19, 2026

Established / Validated

VerifiedMedical

Estriol and Progesterone Treatment May Improve Cognitive Symptoms in Menopausal Women

A case series of twenty menopausal women showed significant improvements in self-reported brain fog, concentration, and memory after twelve months of treatment with a specific estriol and progesterone combination. Preclinical mouse models further suggest that estriol reduces brain inflammation and synaptic loss by targeting estrogen receptor beta in astrocytes.

nature.com

Peer-Reviewed Journal

Last reviewed Sep 19, 2026

Established / Validated

VerifiedMedical

Association of Testosterone and Replacement Therapy with Atrial Fibrillation Risk

This review examines the evolving relationship between testosterone levels and atrial fibrillation (AF), noting that both low and high levels may increase risk. While historical data suggested low testosterone was the primary risk factor, recent clinical trials and population studies indicate a U-shaped relationship where excessive levels from replacement therapy may also trigger arrhythmias.

pmc.ncbi.nlm.nih.gov

Government Health Org

Last reviewed Sep 18, 2026

Established / Validated

VerifiedMedical

Hormone Therapy and Cardiovascular Risk in Midlife Women With Vasomotor Symptoms

This study analyzed data from 2,737 women to estimate the effect of menopausal hormone therapy (MHT) on cardiovascular disease risk among those experiencing hot flashes or night sweats. Researchers found that initiating MHT was associated with a 22% reduction in cardiovascular risk, particularly when started within 10 years of menopause onset.

jamanetwork.com

Last reviewed Sep 18, 2026

Established / Validated

VerifiedMedical

Long-Term Risks of Testosterone Replacement Therapy Following Cervical Spine Fusion Surgery

A retrospective cohort study analyzed the impact of testosterone replacement therapy (TRT) on patients undergoing single-level anterior cervical discectomy and fusion (ACDF). While short-term outcomes were similar to those not on TRT, patients using testosterone showed higher rates of specific spinal complications five years after surgery.

pubmed.ncbi.nlm.nih.gov

Government Health Org

Last reviewed Sep 17, 2026

Showing 9 of 81 validated items.

View Full Evidence Library →

Editorial Series — The Interpretive Layer

The archive answers what is happening. The series help answer what it means.

Where the Evidence Radar surfaces and validates new findings, the Editorial Series sit alongside it as the interpretive layer—translating the evidence into the questions, decisions, and lived realities of the transition.

All Series →

Editorial Series

Biological Transitions with Relational Consequence

"This is not a relationship problem. It is a biological transition that the relational system was never designed to absorb without interpretation."

Read Series →

Editorial Series

Why Communication Advice Often Fails

"This is not a communication problem. It is a relational system operating beyond its functional capacity."

Read Series →

Editorial Series

The Hidden Relational Load

"This is not simply emotional overwhelm. It is the accumulation of invisible relational labor that is no longer being absorbed by the system."

Read Series →

Editorial Series

Relational System Stress

"This is not a relationship breakdown. It is a stable system under sustained stress losing its ability to regulate itself."

Read Series →

Editorial Series

Midlife Transition and Identity

"This is not a phase to fix or optimize. It is a reorganization of identity that changes how a person experiences themselves and their relationships."

Read Series →

Intelligence Toolset

Validated Evidence & Health Literacy

Validate Source Credibility

Enter the URL of any menopause-related news or medical article. Our radar will audit it for scientific citations, editorial standards, and marketing bias.

What this tool does — and does not — evaluate

  • It reviews articles, research sources, and pages containing specific health claims.
  • It does not evaluate practitioners, practices, clinics, organizations, or entire approaches to care.
  • Results describe the evidence characteristics of a page, not the quality, competence, or legitimacy of any person or business.
  • An early-stage or limited evidence base is a descriptive finding, not a negative judgment — it does not mean an approach lacks value.

MenopauseDigest Brief

Receive Evidence-Based Menopause Insights—Without the Noise

Subscribe to the MenopauseDigest Brief (free)

Periodic summaries of new menopause research and reporting, evaluated for credibility and explained in real-world context.

No products. No promotions. No advice—just clarity.

Local-first privacyZero commercial biasUnsubscribe anytime
No sponsored content
No behavioral tracking
Search history, reflections, and translations remain on your device—not our servers

Submit question for consideration

Questions submitted here may inform future coverage or evidence-grounded Q&A. We cannot respond individually and do not provide medical advice.

0 / 700
Restoring Agency Through Inquiry